Get the Stockscreener App
23.29
2.27%
-0.54
After Hours:
23.11
-0.18
-0.77%
Arcus Biosciences Inc stock is traded at $23.29, with a volume of 1.03M.
It is down -2.27% in the last 24 hours and down -8.42% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$23.83
Open:
$23.81
24h Volume:
1.03M
Relative Volume:
0.57
Market Cap:
$2.88B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-7.5372
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+0.87%
1M Performance:
-8.42%
6M Performance:
+171.13%
1Y Performance:
+53.93%
1-Day Range:
$22.71
$23.99
1-Week Range:
$22.60
$24.16
52-Week Range:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
23.29 | 2.95B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Portfolio Shifts: Is Arcus Biosciences Inc stock a buy for dividend growthLong Setup & AI Powered Buy and Sell Recommendations - moha.gov.vn
Insider Sell: Goeltz II Robert C. Sells Shares of Arcus Bioscien - GuruFocus
Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 6,552 Shares of Stock - MarketBeat
The Technical Signals Behind (RCUS) That Institutions Follow - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Trading Up 2.8%Should You Buy? - MarketBeat
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Stock Optios of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Is Arcus Biosciences Inc a good long term investmentDebt-to-Equity Ratio Analysis & AI-Based Predictions Available Free - earlytimes.in
Arcus Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (RCUS) - news.stocktradersdaily.com
Can Arcus Biosciences Inc. stock deliver consistent earnings growthQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Have Insiders Sold Arcus Biosciences Shares Recently? - simplywall.st
Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
Can Arcus Biosciences Inc. stock deliver sustainable ROEMarket Sentiment Report & Technical Confirmation Trade Alerts - Улправда
How higher bond yields impact Arcus Biosciences Inc. stockJuly 2025 Breakouts & Safe Entry Trade Signal Reports - ulpravda.ru
Is Arcus Biosciences Inc. stock attractive after correctionEarnings Growth Summary & Weekly Stock Performance Updates - Bölüm Sonu Canavarı
Market Outlook: Can Arcus Biosciences Inc. stock maintain operating marginsQuarterly Market Summary & Daily Entry Point Trade Alerts - DonanımHaber
Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 4,343 Shares of Stock - MarketBeat
Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock - MarketBeat
Robert Goeltz II Sells 6,702 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) CEO Sells $633,360.36 in Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock - MarketBeat
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com Nigeria
Arcus Biosciences Insider Sold Shares Worth $466,870, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $278,739, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $318,496, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
Officer Azoy Sells 4,343 ($96.6K) Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
Palmetto Grain Brokerage - Palmetto Grain Brokerage
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? - Barchart.com
Officer Markus Files To Sell 10,000 Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
Pres Jaen Files To Sell 22,000 Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
Arcus Biosciences (NYSE: RCUS) shareholder files Rule 144 to sell 5,000 shares - Stock Titan
RCUS Stock Down on Decision to Discontinue GILD Partnered Study - Finviz
Arcus Biosciences stock price target raised to $32 at H.C. Wainwright - Investing.com Canada
Domvanalimab failure bad news for Arcus and TIGIT class - The Pharma Letter
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy - simplywall.st
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - MSN
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update - ts2.tech
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Yahoo Finance
Arcus Biosciences (NYSE:RCUS) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):